Investors Should Take Note Of Autolus Therapeutics plc (AUTL)

After grabbing 15.0 million shares, the institutional investor is now in possession of 15.0 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.67% having worth around $27.15 million. Moreover, TFG Asset Management UK LLP increased its share by 1.7 million to have a control over 10.0 million shares. And Tetragon Financial Management LP raised its holdings to 9.46 million shares by acquiring 9.46 million shares or 5.47% of the stake.

Autolus Therapeutics plc (AUTL) concluded trading on 05/24/23 at a closing price of $3.11, with 1.46 million shares of worth about $4.55 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 35.22% during that period and on Wednesday the price saw a loss of about -2.51%. Currently the company’s common shares owned by public are about 173.07M shares, out of which, 158.45M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 11 analysts are covering the AUTL stock and their offered price forecasts bring an average price target of $6.63. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $12.00 and could fall to a lowest price of $2.70. The stock’s current price level is 57.4% above of average price target set by the analysts, while a rise to estimated low would result in loss of -15.19% for the stock. However, touching the estimated high of $12.00 would mean a gain of 74.08% for the stock.

iShares Biotechnology ETF, Crown Sigma UCITS Plc – LGT Crown, and Regnan UFI – Regnan Global Equity are the top 3 mutual funds which are holding stakes in Autolus Therapeutics plc iShares Biotechnology ETF is currently holding 0.84 million shares of worth totaling $1.52 million. The company recently came selling 1394.0 shares which brought its stake up to 0.49% of the company’s outstanding shares. Regnan UFI – Regnan Global Equity, after buying 0.51 million shares, have now control over 0.30% of the stake in the company. It holds 96957.0 shares of worth $0.93 million.

Autolus Therapeutics plc (NASDAQ: AUTL) started trading at $3.22, above $0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 3.1500, or with a loss of -2.51%. Stock saw a price change of 5.42% in past 5 days and over the past one month there was a price change of 79.77%. Year-to-date (YTD), AUTL shares are showing a performance of 63.68% which increased to 14.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.60 but also hit the highest price of $3.79 during that period. The average intraday trading volume for Autolus Therapeutics plc shares is 585.68K. The stock is currently trading 40.06% above its 20-day simple moving average (SMA20), while that difference is up 54.53% for SMA50 and it goes to 32.14% higher than SMA200.

Qatar Investment Authority acquired 15.0 million shares of Autolus Therapeutics plc having value of about $27.15 million. Autolus Therapeutics plc (NASDAQ: AUTL) currently have 173.07M outstanding shares and institutions hold larger chunk of about 30.20% of that. Holding of mutual funds in the company is about 1.59% while other institutional holders and individual stake holders have control over 59.42% and — of the stake respectively.

The stock has a current market capitalization of $503.51M and its 3Y-monthly beta is at 1.50. It has posted earnings per share of -$1.59 in the same period. It has Quick Ratio of 9.90 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUTL, volatility over the week remained 12.34% while standing at 10.85% over the month.

Analysts are in expectations that Autolus Therapeutics plc (AUTL) stock would likely to be making an EPS of -$0.22 in the current quarter, while forecast for next quarter EPS is -$0.22 and it is -$0.85 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.28 which is -$0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.46 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 20.50% while it is estimated to increase by 4.50% in next year.

Analysts at 11 brokerage firms have issued recommendations for the Autolus Therapeutics plc (AUTL)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 11 Wall Street analysts, 8 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.